2 completed, 1 active not recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow dose 3: new trials by email Literature Review of dose 3 trials Research Report on dose 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of ETD-001 Gel Dose 1, dose 2, dose 3 - Safety Issues | Phase 1 | Completed | Etern Therapeutics Wuxi Limited | 56 | 2026-03-16 | 2026-09-10 |
| Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Dose 1, Dose 2, Dose 0 - Diabetes Prevention | Phase 1 | Completed | Pennington Biomedical Research Center | 64 | 2014-02-01 | 2019-03-21 |
| Transfer of Genetically Engineered Lymphocytes in Melanoma Patients Dose 1, Dose 2, Dose 3 - Melanoma | Phase 1 | Active not recruiting | Loyola University | 14 | 2012-07-01 | 2020-10-30 |
Melanoma (1)
Etern Therapeutics Wuxi Limited (1) · Loyola University (1) · Pennington Biomedical Research Center (1)
United States (2) · China (1)
Jennifer C Rood, Ph.D. (1) · Michael Nishimura, PhD (1)
P01CA154778 (1), P50AT002776 (1), R44CA126461 (1)